{"product_id":"mylicon-bambini-66-6-mg-30-ml-gocce-orali","title":"Mylicon children 66.6 mg 30 ml oral drops","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of gastrointestinal meteorism and aerophagia in infants and children.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e1 ml of solution contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: simethicone (activated dimethylpolysiloxane) 66.6 mg. \u003ci\u003eExcipient with known effects\u003c\/i\u003e: sodium, sodium benzoate, ethanol, propylene glycol. For the full list of excipients, see 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCitric acid monohydrate; sodium citrate; methylhydroxypropylcellulose; carboxypolymethylene; saccharin; sodium benzoate; sorbic acid; sodium bicarbonate; raspberry essence; concentrated vanilla essence; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the components listed in paragraph 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003cu\u003eInfants and children\u003c\/u\u003e: 20 drops (= 0.6 ml), 2-4 times a day preferably after meals or otherwise according to medical prescription. \u003cb\u003eDo not exceed the recommended doses.\u003c\/b\u003e After a short period of treatment (7 days) without appreciable results, consult your doctor. \u003cu\u003eMethod of administration\u003c\/u\u003e Shake well before use. The drops should be dispersed in a little water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not exceed the recommended doses. After a short period of treatment (7 days) without appreciable results, consult your doctor. In case of persistence, worsening of symptoms, or if new symptoms appear or in case of prolonged constipation, treatment should be discontinued and the patient should consult his doctor. Do not use in case of suspected intestinal perforation or ileus. \u003ci\u003eImportant information about some excipients:\u003c\/i\u003e MYLICON contains: • less than 1mmol of \u003cb\u003e \u003ci\u003esodium\u003c\/i\u003e \u003c\/b\u003e (23 mg) per dose (20 drops). It can therefore be considered essentially sodium-free; • 0.6 mg of \u003cb\u003e \u003ci\u003esodium benzoate\u003c\/i\u003e \u003c\/b\u003e per dose (20 drops) equivalent to 0.17 mg\/kg for a 3.5 kg newborn and 0.03 mg\/kg for a 20 kg child. The increase in bilirubin levels following its detachment from albumin can increase neonatal jaundice which can evolve into kernicterus (deposits of unconjugated bilirubin in the brain tissue); • 0.7025 mg of \u003cb\u003e \u003ci\u003epropylene glycol\u003c\/i\u003e \u003c\/b\u003e for each dose (20 drops), equivalent to 1.17 mg\/ml. Coadministration with any alcohol dehydrogenase substrate such as ethanol may induce serious adverse effects in neonates. • 0.174 mg of \u003cb\u003e \u003ci\u003eethanol\u003c\/i\u003e \u003c\/b\u003e in each single dose (20 drops) which is equivalent to 0.290 mg\/ml. The amount of this medicine is equivalent to less than 0.00435 ml of beer or 0.00174 of wine. This medicine contains a quantity of ethanol that does not produce significant effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTaking SIMETICONE and mineral oil (paraffin) laxatives at the same time is not recommended, as the combination of these two products reduces their effectiveness.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects observed during treatment in clinical studies and integrated with those collected during post-marketing experience are listed in the table below according to System Organ Class (using MedDRA terminology) and according to the following frequency: Very common ≥ 1\/10 Common ≥ 1\/100 and \u003c 1\/10; Uncommon ≥ 1\/1,000 and \u003c 1\/100; Rare ≥ 1\/10,000 and \u003c 1\/1,000; Very rare \u003c 1\/10,000\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Vomiting, diarrhoea, abdominal pain, ileus, nausea.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eVery rare: Angioedema Rash.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003erare: hypersensitivity reactions.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePediatric population\u003c\/u\u003e Simethicone is a chemically inert substance, pharmacologically inactive and not absorbed from the gastrointestinal tract. Simethicone is also eliminated unchanged in the faeces. Accidental exposure to the product by children revealed no symptoms in most cases. The reported symptoms were mild to moderate in nature and can be explained by the pre-existing condition.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003ePregnancy\u003c\/u\u003e.\u003c\/i\u003e There are no adequate data on the use of Mylicon in pregnant women, therefore it should not be used during pregnancy unless clearly necessary and after a risk\/benefit assessment by the doctor. \u003ci\u003e \u003cu\u003eBreastfeeding\u003c\/u\u003e.\u003c\/i\u003e It is not known whether simethicone is excreted in breast milk. The excretion of simethicone in breast milk has not been studied in animals. The decision whether to continue\/discontinue breastfeeding or to continue\/discontinue simethicone therapy should be made taking into account the benefit of breastfeeding for the infant and of simethicone therapy for the woman. Consult a doctor before taking Mylicon during pregnancy or breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo effects on the ability to drive or use machines are reported.\u003c\/p\u003e","brand":"Johnson \u0026 Johnson","offers":[{"title":"Default Title","offer_id":51730208424263,"sku":"020708069","price":19.03,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/johnson-johnson-spa-mylicon-bambini-66-6-mg-30-ml-gocce-orali-farmacia-dottor-tili-1213791074.jpg?v=1767154329","url":"https:\/\/www.dottortili.com\/en-eu\/products\/mylicon-children-66-6-mg-30-ml-oral-drops","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}